Table 3.

Grouping stratified by 20q13 gain, centrosome amplification, and clinicopathologic variables

FactorCategoryGroup 1
Group 2
Group 3
P
20q13 gain+*
20q13 gain-and CA+
20q13 gain-and CA−
n = 42n = 22n = 36
CIN+4072<0.0001
21534
DNA ploidyAneuploid4061<0.0001
Diploid21635
DNA index1.85 ± 0.561.18 ± 0.321.03 ± 0.14<0.0001
Tumor numberMultiple3412150.0015
Single81021
Tumor shapeNonpapillary6330.6970
Papillary361933
Urine cytologyPositive2875<0.0001
Negative91426
Tumor gradeG33362<0.0001
G2 and G191634
Tumor stage≥pT212550.0341
pT127921
pTa3810
Tumor recurrence+2212110.0417
15621
Disease progression+12710.0031
251131
  • * All 20q13 gain tumors had CA+ and Aurora-A overexpression.

  • False-positive tumors were defined as negative.

  • Patient prognosis could be evaluated in 87 ≤pT2 tumors that had curative surgery.